SCHEMBL4670968

SCHEMBL4670968

O=C(O)/C(O)=C/C(=O)c1ccoc1Cc1cccc(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 2/20 0.39
LMNA P02545 2/20 0.39
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ALDH1A1 P00352 2/20 0.37
IDH1 O75874 1/20 0.36
GPR52 Q9Y2T5 1/20 0.36
KDM4E B2RXH2 1/20 0.36
SLC1A1 P43005 2/20 0.36
GAA P10253 1/20 0.36
POLB P06746 2/20 0.35
THRB P10828 1/20 0.35
NR4A2 P43354 1/20 0.35
ESR1 P03372 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
NR3C2 P08235 1/20 0.35
KDM5A P29375 1/20 0.35
KDM5B Q9UGL1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4670971 1.00 HCAR2 (0.39) HCAR2LMNANPC1MAPTRAB9A
SCHEMBL4676250 0.87 CYP2C19 (0.40) NPC1MAPTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL4676253 0.87 CYP2C19 (0.40) NPC1MAPTRAB9ASMN1; SMN2ALDH1A1
SCHEMBL4675011 0.86 TP53 (0.35) LMNANPC1MAPTRAB9ASMN1; SMN2
SCHEMBL4675005 0.86 TP53 (0.35) LMNANPC1MAPTRAB9ASMN1; SMN2
SCHEMBL29888749 0.84 HCAR2 (0.47) HCAR2LMNAALDH1A1KDM4ESLC1A1
SCHEMBL28884932 0.84 HCAR2 (0.47) HCAR2LMNAALDH1A1KDM4ESLC1A1
SCHEMBL4679732 0.81 HCAR2 (0.38) HCAR2LMNANPC1MAPTRAB9A
SCHEMBL4679731 0.81 HCAR2 (0.38) HCAR2LMNANPC1MAPTRAB9A
SCHEMBL4674272 0.80 HCAR2 (0.36) HCAR2LMNANPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HCAR2 276/4885LMNA 659/4885NPC1 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.